beta-hydroxyisovalerate

beta-hydroxyisovalerate (CAS No.: 625-08-1) is an endogenous branched-chain hydroxy acid derived from L-leucine metabolism via an α-ketoisocaproate intermediate, and is commonly detected in human urine as part of normal metabolic turnover. It is widely studied as a metabolic biomarker, with urinary elevations serving as an early and sensitive indicator of biotin deficiency and being associated with metabolic dysregulation such as type II diabetes. Functionally, beta-hydroxyisovalerate has been implicated in the modulation of proteostasis and inflammatory signaling, including attenuation of proteolysis-inducing factor-mediated increases in 20S proteasome activity and inhibition of NF-κB nuclear accumulation in skeletal muscle cell models, suggesting a role in regulating protein degradation pathways. In preclinical models of cachexia, administration has been shown to suppress muscle protein breakdown and promote protein synthesis, supporting its relevance in studies of muscle wasting and metabolic disorders. As a biologically active metabolite linked to amino acid catabolism, it is utilized in biochemical and metabolic research to investigate nutrient signaling, mitochondrial function, and metabolic flux, as well as in drug discovery efforts targeting muscle atrophy and metabolic disease pathways. In vitro studies typically employ concentrations in the low micromolar range, while in vivo dosing regimens vary depending on experimental design, reflecting its use across diverse cellular and animal models to elucidate metabolic and signaling mechanisms.